- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05012072
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention (MLI)
March 12, 2024 updated by: Roberta Jeanne Ruiz, Microgen LLC
Reductions in Biopsychosocial Risks for Pregnant Latinas and Their Infants: The Mastery Lifestyle Intervention
This randomized controlled trial will test an intervention called the Mastery Lifestyle Intervention (the MLI) that was developed from data of 1000+pregnant Hispanic women related to risks of preterm birth.
The investigators will deliver a psychoeducational intervention that is manualized over 6 group sessions.
The investigators will also have a usual care group that receives standard prenatal care.
The investigators plan to enroll 221 pregnant women and start the study with them at 14-20 weeks gestation.
The investigators will also test the biological response of the intervention by measuring Corticotropin Releasing Hormone, progesterone, estriol, and test for cotinine.
The investigators will also determine any effect on infant outcomes at delivery.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
To address the gaps related to interventions for Hispanic Mexican American and African American pregnant women, the investigators have developed and successfully pilot tested the Mastery Lifestyle Intervention (MLI): a culturally-relevant, manualized psychosocial group intervention that integrates two evidence-based behavioral therapies - Acceptance and Commitment Therapy (ACT) and Problem-Solving Therapy (PST).
The MLI is a 6-week program designed to be integrated into regular prenatal care to facilitate more comprehensive care delivered by a nurse practitioner (NP) or certified nurse midwife (CNM).
We propose the following hypotheses for a randomized controlled trial: Hypothesis 1a: Participants in the 6-week MLI will have decreased depressive symptoms, anxiety, stress, disengaged coping, and increased active coping compared to UC at end-of-treatment and after 6 weeks.
Hypothesis 1b: The effects of MLI versus UC on depression, anxiety, stress, acculturative stress, and coping will be mediated via psychological flexibility and moderated by acculturation.
Hypothesis 2a: Compared to UC, MLI participants will have significantly lower mean levels of CRH over time from baseline to end-of-treatment.
Hypothesis 2b: Compared to UC, MLI participants will have significantly higher progesterone levels and lower estriol levels (higher progesterone/estriol ratios) over time from baseline to end-of-treatment.
Hypothesis 3: As compared to UC, infants from mothers in the MLI group will have longer gestational age, greater birth weight, and fewer NICU admissions.
Study Type
Interventional
Enrollment (Estimated)
221
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Roberta J. Ruiz, PhD
- Phone Number: 2813005265
- Email: jruiz@microgenlabs.com
Study Contact Backup
- Name: Raymond P Stowe, PhD
- Phone Number: 2814154073
- Email: rpstowe@microgenlabs.com
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77054
- Recruiting
- Anthony Chavez, MD
-
Contact:
- Roberta J Ruiz, PhD
- Phone Number: 281-300-5265
- Email: jruiz@microgenlabs.com
-
Contact:
- Raymond P Stowe, PhD
- Phone Number: 12814154073
- Email: rpstowe@microgenlabs.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Providing informed consent;
- Ability to read and speak English or Spanish
- Pregnant at 14-20 weeks gestation with one fetus, gestational dating will be reviewed before enrollment via ultrasound administered per standard of care
- Intrauterine pregnancy
- Self-identification as Latina of Mexican heritage or African American
- Age 18 to 45 years
- Born in Mexico or U.S. born and currently living in the U.S.
- Medicaid or other government supported insurance
- Women who score 10 or greater on the Center for Epidemiological Studies Depression Scale (CES-D) OR 5 or greater on the Generalized Anxiety Disorder-7 scale (GAD-7), or 14 or > on the Perceived Stress Scale as administered by clinical staff of the participating provider
- Willingness to adhere to the MLI regimen or usual care regimen
- Women who develop GDM after enrollment in the study will remain in the study. °Development of hypertension or preeclampsia, pyelonephritis, or GDM will be considered an effect modifier in analysis of infant outcomes.
Exclusion Criteria:
After initial review of the electronic health record (EHR):
- Major systemic infections such as HIV, hepatitis
- <18 years of age
- Enrollment in a prenatal program such as the Nurse Family Partnership
- Severe cognitive or psychiatric impairment per judgment of providers, that precludes cooperation with study protocol
- Inability to read English or Spanish
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MLI Experimental group
6 group sessions over 6 weeks with pregnant Latinas and African Americans starting at 14-20 weeks to 20-26 weeks in their prenatal care setting.
|
Combination cognitive behavioral intervention of phase 3 CBT using ACT and PST
|
No Intervention: Control usual prenatal care
Only data collection but no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anxiety
Time Frame: Assessing change over time: 14-20 weeks, 20-26 weeks, 32-36 weeks pregnant
|
Self Report questionnaire GAD-7
|
Assessing change over time: 14-20 weeks, 20-26 weeks, 32-36 weeks pregnant
|
Depression
Time Frame: Assessing change over time:14-20 weeks, 20-26 weeks, 32-36 weeks pregnant
|
Self Report questionnaire CES-D
|
Assessing change over time:14-20 weeks, 20-26 weeks, 32-36 weeks pregnant
|
Stress
Time Frame: Assessing change over time:14-20 weeks, 20-26 weeks, 32-36 weeks pregnant
|
Self Report questionnaire-PSS
|
Assessing change over time:14-20 weeks, 20-26 weeks, 32-36 weeks pregnant
|
Coping levels
Time Frame: Assessing change over time:14-20 weeks, 20-26 weeks, 32-36 weeks pregnant
|
Self Report questionnaire The Brief Cope
|
Assessing change over time:14-20 weeks, 20-26 weeks, 32-36 weeks pregnant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To explore the effect of the MLI, versus a usual care group, on the neuroendocrine risk factor of preterm birth (Corticotropin Releasing Hormone (CRH).from baseline to end-of treatment.
Time Frame: Assessing change over time:14-20 weeks gestation, 20-26 weeks gestation
|
Corticotropin Releasing Hormone is part of the maternal fetal responses to stress, anxiety, and depressive symptoms.
|
Assessing change over time:14-20 weeks gestation, 20-26 weeks gestation
|
To explore the effect of the MLI, versus a usual care group, on neuroendocrine risk factors (progesterone) on preterm birth from baseline to end-of treatment.
Time Frame: Assessing change over time:14-20 weeks gestation, 20-26 weeks gestation
|
Progesterone is part of the maternal fetal responses to stress, anxiety, and depressive symptoms.
|
Assessing change over time:14-20 weeks gestation, 20-26 weeks gestation
|
To explore the effect of the MLI, versus a usual care group, on the neuroendocrine risk factor of Estriol.
Time Frame: Assessing change over time:14-20 weeks gestation, 20-26 weeks gestation
|
Estriol is part of the maternal fetal response to stress, anxiety, and depressive symptoms.
|
Assessing change over time:14-20 weeks gestation, 20-26 weeks gestation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To explore the effect of the MLI on infant gestational age at birth
Time Frame: After delivery
|
Health outcomes of the infants after usual care or after treatment with the intervention to further determine efficacy.
|
After delivery
|
To explore the effect of the MLI on infant birthweight
Time Frame: After Delivery
|
Health outcomes of the infants after usual care or after treatment with the intervention to further determine efficacy.
|
After Delivery
|
To explore the effect of the MLI on infants being admitted to the Neonatal Intensive Care Unit
Time Frame: After Delivery
|
Health outcomes of the infants after usual care or after treatment with the intervention to further determine efficacy.
|
After Delivery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Roberta J Ruiz, PhD, Microgen Laboratories LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ruiz RJ, Grimes K, Spurlock E, Stotts A, Northrup TF, Villarreal Y, Suchting R, Cernuch M, Rivera L, Stowe RP, Pickler RH. The mastery lifestyle intervention to reduce biopsychosocial risks for pregnant Latinas and African Americans and their infants: protocol for a randomized controlled trial. BMC Pregnancy Childbirth. 2022 Dec 28;22(1):979. doi: 10.1186/s12884-022-05284-9.
- Ruiz RJ, Newman M, Records K, Wommack JC, Stowe RP, Pasillas RM. Pilot Study of the Mastery Lifestyle Intervention. Nurs Res. 2019 Nov/Dec;68(6):494-500. doi: 10.1097/NNR.0000000000000384.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2021
Primary Completion (Estimated)
December 20, 2025
Study Completion (Estimated)
February 1, 2026
Study Registration Dates
First Submitted
July 27, 2021
First Submitted That Met QC Criteria
August 11, 2021
First Posted (Actual)
August 19, 2021
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 12, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preterm Birth
-
e-Bio CorpRecruitingPreterm Labor | PreTerm Birth | Preterm Labor With Delivery NosUnited States
-
Thomas Jefferson UniversityCompleted
-
Chelsea and Westminster NHS Foundation TrustSPD Development Company Limited; Borne CharityRecruitingPreterm Birth | Preterm Labor | Preterm Birth Complication | Preterm Premature Rupture of Membrane | Preterm PregnancyUnited Kingdom
-
Cairo UniversityCompleted
-
University of OklahomaCompletedPreTerm Birth | PreTerm NeonateUnited States
-
PreTeL, IncDuke University; University of RochesterRecruitingPreterm Birth | Threatened Preterm Labor | PreTerm LaborUnited States
-
Federico II UniversityRecruiting
-
University of OxfordShoklo Malaria Research UnitCompleted
-
Eunice Kennedy Shriver National Institute of Child...CompletedPregnancy | Preterm Birth | Preterm LaborUnited States
-
University Hospital Inselspital, BerneAmniSure International LLCCompletedPreterm Birth | Preterm LabourSwitzerland
Clinical Trials on The Mastery Lifestyle Intervention
-
Northwestern UniversityNot yet recruitingCoronary Artery Disease | Coronary Artery Bypass | Surgery | Hemorrhage Postoperative | Patient Care Team
-
Sheba Medical CenterD-Cure, Israel; Chief Scientist, The Israel Ministry of ScienceCompleted
-
Emory UniversityCompleted
-
Northwestern UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedHyperglycemia | Glucose Metabolism Disorders | Metabolic Diseases | Obesity | Diabetes Mellitus | Endocrine System Diseases | Overnutrition | Nutrition Disorders | Overweight | Body Weight | Signs and SymptomsUnited States
-
Baylor College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Michael... and other collaboratorsActive, not recruiting
-
Laval UniversityActive, not recruitingPhysical Activity | Weight Loss | Dietary Modification | BreastfeedingCanada
-
University of AdelaideCompletedInsulin Resistance | Type 2 DiabetesAustralia
-
Molde University CollegeNorwegian Labour and Welfare AdministrationCompletedObesity | Morbid Obesity | Work Related Illnesses | Life Style | Sick-leave
-
Mayo ClinicCompletedObesityUnited States
-
DongGuk UniversityNational Research Foundation of KoreaUnknown